Cargando…

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease

INTRODUCTION: The REGAL (RSV evidence—a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paes, Bosco, Fauroux, Brigitte, Figueras-Aloy, Josep, Bont, Louis, Checchia, Paul A., Simões, Eric A. F., Manzoni, Paolo, Carbonell-Estrany, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125140/ https://www.ncbi.nlm.nih.gov/pubmed/27864751 http://dx.doi.org/10.1007/s40121-016-0137-7

Ejemplares similares

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease
por: Checchia, Paul A., et al.
Publicado: (2017)

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases
por: Manzoni, Paolo, et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease
por: Figueras-Aloy, Josep, et al.
Publicado: (2016)

Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
por: Bont, Louis, et al.
Publicado: (2016)

The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood
por: Fauroux, Brigitte, et al.
Publicado: (2017)

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
por: Simões, Eric A. F., et al.
Publicado: (2018)

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
por: Simões, Eric AF, et al.
Publicado: (2008)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018)

The effects of varying protein and energy intakes on the growth and body composition of very low birth weight infants
por: Costa-Orvay, Juan Antonio, et al.
Publicado: (2011)

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
por: Keary, Ian P., et al.
Publicado: (2023)

Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia
por: Botet, Francesc, et al.
Publicado: (2012)

Introduction. RSV and RAD: possibilities for prevention? The link between respiratory syncytial virus and reactive airway disease
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2002)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children
por: Simões, Eric A.F., et al.
Publicado: (2010)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
por: Lanari, M., et al.
Publicado: (2020)

Fail-Fast in Respiratory Syncytial Virus Vaccine Development
por: Besteman, Sjanna B., et al.
Publicado: (2019)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants
por: Butt, Michelle, et al.
Publicado: (2023)

Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])
por: Carbonell‐Estrany, Xavier, et al.
Publicado: (2018)

Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt
por: De Luca, Daniele, et al.
Publicado: (2023)

Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step
por: Billard, Marie-Noëlle, et al.
Publicado: (2021)

Global Respiratory Syncytial Virus–Related Infant Community Deaths
por: Mazur, Natalie I, et al.
Publicado: (2021)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

Neutrophils in respiratory syncytial virus infection: A target for asthma prevention
por: Geerdink, Ruben J., et al.
Publicado: (2015)

Respiratory syncytial virus (RSV) disease – new data needed to guide future policy
por: Campbell, Harry, et al.
Publicado: (2015)

Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study
por: Blanken, Maarten O., et al.
Publicado: (2013)

The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis
por: Simões, Eric A F
Publicado: (2022)

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
por: Simões, Eric A. F., et al.
Publicado: (2015)

COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works
por: Gastaldi, Andrea, et al.
Publicado: (2021)

The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial
por: Ermers, Marieke J J, et al.
Publicado: (2009)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
por: Papenburg, Jesse, et al.
Publicado: (2012)

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)
por: Wang, Daniel Y., et al.
Publicado: (2017)

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2011)

Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union
por: van Beek, Dianne, et al.
Publicado: (2013)

The disease burden of respiratory syncytial virus in Infants
por: Munro, Alasdair P.S., et al.
Publicado: (2023)

Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysis
por: Stein, Renato T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u4p2v1o9jsnkttd2sc7k8bg2q6